← Leaderboards
Cary P Gross
Yale University
$11,062,635
Attributed
$14,036,134
Total exposure
10
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,432,580 · 8
AHRQ$603,554 · 2
By mechanism
R01$12,218,664 · 6
K08$731,967 · 1
R21$603,554 · 2
K07$481,949 · 1
Top collaborators
- Emily Ai-Hua Wang5 shared
- Dowin Boatright3 shared
- Michaela Ann Dinan3 shared
Most similar at Yale University
Same institution · by research overlap
- Peter M Glazer$37,467,142
- Emily Ai-Hua Wang$23,629,797
- Julia Rozanova$2,189,619
- Allen Everett Bale$6,957,737
- Ravinder Nath$4,400,240
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsCancer CareHealth SystemDiagnosisMedicareInnovationCaringNovel StrategiesProviderPoliciesSocioeconomicsMalignant Neoplasm Of LungComplexRacial DisparityPublic HealthRaceSocioeconomic StatusAdoptedAffectBeneficiaryCancer Health DisparityHealthcare SystemsCharacteristicsInsurance
Grant awards (34)
Factors Associated with High Quality Care for Patients with Lung Cancer$681,277
R01 · FY2025 · MD · contact PI
Broad Genomic Profiling in patients with advanced lung cancer: empirically assessing adoption, clinical utility, and the value of additional evidence in an evolving landscape of cancer care$653,926
R01 · FY2025 · CA · contact PI
Diversity in the Cancer Care Workforce$626,367
R01 · FY2025 · MD · contact PI
Diversity in the Cancer Care Workforce$690,483
R01 · FY2024 · MD · contact PI
Broad Genomic Profiling in patients with advanced lung cancer: empirically assessing adoption, clinical utility, and the value of additional evidence in an evolving landscape of cancer care$628,231
R01 · FY2024 · CA · contact PI
Health System and Contextual Factors Associated with Racial Equity in Lung Cancer Care$605,008
R01 · FY2024 · MD · contact PI
Diversity in the Cancer Care Workforce$858,849
R01 · FY2023 · MD · contact PI
Broad Genomic Profiling in patients with advanced lung cancer: empirically assessing adoption, clinical utility, and the value of additional evidence in an evolving landscape of cancer care$706,720
R01 · FY2023 · CA · contact PI
Health System and Contextual Factors Associated with Racial Equity in Lung Cancer Care$630,840
R01 · FY2023 · MD · contact PI
Health System and Contextual Factors Associated with Racial Equity in Lung Cancer Care$629,894
R01 · FY2022 · MD · contact PI
Incarceration and Cancer-Related Outcomes (ICRO)$278,624
R01 · FY2022 · CA
Incarceration and Cancer-Related Outcomes (ICRO)$582,590
R01 · FY2021 · CA
Incarceration and Cancer-Related Outcomes (ICRO)$77,305
R01 · FY2020 · CA
Incarceration and Cancer-Related Outcomes (ICRO)$399,825
R01 · FY2019 · CA
Incarceration and Cancer-Related Outcomes (ICRO)$444,079
R01 · FY2018 · CA
Impact of Social contagion on Physician use of unproven cancer interventions$543,730
R01 · FY2017 · CA · contact PI
Impact of Social contagion on Physician use of unproven cancer interventions$533,168
R01 · FY2016 · CA · contact PI
Impact of Social contagion on Physician use of unproven cancer interventions$644,255
R01 · FY2015 · CA · contact PI
Impact of Social contagion on Physician use of unproven cancer interventions$501,190
R01 · FY2014 · CA · contact PI
Use and Outcomes of Radiation Therapy for Medicare Patients with Common Cancers$369,181
R01 · FY2012 · CA · contact PI
Use and Outcomes of Radiation Therapy for Medicare Patients with Common Cancers$469,652
R01 · FY2011 · CA · contact PI
Use and Outcomes of Radiation Therapy for Medicare Patients with Common Cancers$663,470
R01 · FY2010 · CA · contact PI
Multimorbidity and Cancer Screening: Achieving Patient Understanding$175,245
R21 · FY2010 · HS · contact PI
Multimorbidity and Screening Colonoscopy: A Framework for Patients and Policy$138,724
R21 · FY2009 · HS · contact PI
Multimorbidity and Cancer Screening: Achieving Patient Understanding$124,095
R21 · FY2009 · HS · contact PI
Multimorbidity and Screening Colonoscopy: A Framework for Patients and Policy$165,490
R21 · FY2008 · HS · contact PI
The Impact of Comorbidity on Older Cancer Patients$179,257
K08 · FY2007 · AG · contact PI
The Impact of Comorbidity on Older Cancer Patients$190,337
K08 · FY2006 · AG · contact PI
The Impact of Comorbidity on Older Cancer Patients$185,630
K08 · FY2005 · AG
The Impact of Comorbidity on Older Cancer Patients$176,743
K08 · FY2004 · AG
Barriers to Enrolling the Elderly in Cancer Trials$137,700
K07 · FY2004 · CA
Barriers to Enrolling the Elderly in Cancer Trials$137,700
K07 · FY2003 · CA
Barriers to Enrolling the Elderly in Cancer Trials$68,850
K07 · FY2002 · CA
Barriers to Enrolling the Elderly in Cancer Trials$137,699
K07 · FY2001 · CA